A Five-lncRNAs Signature-Derived Risk Score Based on TCGA and CGGA for Glioblastoma: Potential Prospects for Treatment Evaluation and Prognostic Prediction
Open Access
- 17 December 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10
Abstract
Accumulating studies have confirmed the crucial role of long non-coding RNAs (ncRNAs) as favorable biomarkers for cancer diagnosis, therapy, and prognosis prediction. In our recent study, we established a robust model which is based on multi-gene signature to predict the therapeutic efficacy and prognosis in glioblastoma (GBM), based on Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) databases. lncRNA-seq data of GBM from TCGA and CGGA datasets were used to identify differentially expressed genes (DEGs) compared to normal brain tissues. The DEGs were then used for survival analysis by univariate and multivariate COX regression. Then we established a risk score model, depending on the gene signature of multiple survival-associated DEGs. Subsequently, Kaplan-Meier analysis was used for estimating the prognostic and predictive role of the model. Gene set enrichment analysis (GSEA) was applied to investigate the potential pathways associated to high-risk score by the R package “cluster profile” and Wiki-pathway. And five survival associated lncRNAs of GBM were identified: LNC01545, WDR11-AS1, NDUFA6-DT, FRY-AS1, TBX5-AS1. Then the risk score model was established and shows a desirable function for predicting overall survival (OS) in the GBM patients, which means the high-risk score significantly correlated with lower OS both in TCGA and CGGA cohort. GSEA showed that the high-risk score was enriched with PI3K-Akt, VEGFA-VEGFR2, TGF-beta, Notch, T-Cell pathways. Collectively, the five-lncRNAs signature-derived risk score presented satisfactory efficacies in predicting the therapeutic efficacy and prognosis in GBM and will be significant for guiding therapeutic strategies and research direction for GBM.Keywords
This publication has 39 references indexed in Scilit:
- A preliminary quantitative proteomic analysis of glioblastoma pseudoprogressionProteome Science, 2015
- limma powers differential expression analyses for RNA-sequencing and microarray studiesNucleic Acids Research, 2015
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- Comparison of software packages for detecting differential expression in RNA-seq studiesBriefings in Bioinformatics, 2013
- Genome-Wide RNAi Screening Identifies Genes Inhibiting the Migration of Glioblastoma CellsPLOS ONE, 2013
- ggbio: an R package for extending the grammar of graphics for genomic dataGenome Biology, 2012
- Independent and functional validation of a multi-tumour-type proliferation signatureBritish Journal of Cancer, 2012
- PTBP1‐dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesisMolecular Carcinogenesis, 2011
- What should physicians look for in evaluating prognostic gene-expression signatures?Nature Reviews Clinical Oncology, 2010
- Endothelial endostatin release is induced by general cell stress and modulated by the nitric oxide/cGMP pathwayThe FASEB Journal, 2003